Injectable formulation of bisphosphonate (pamidronate, alendronate, incadronate, and zoledronate) is available only for therapy of malignancy in Japan. Ibandronate and zoledronate are permitted to use by injection in the treatment of osteoporosis in US and Europe and have shown a significant effect in fracture prevention. Recently, it was reported that an annual infusion of zoledronate was associated with improved survival in addition to a reduction in the rate of new fractures. Injectable formulation of ibandronate is now in the 3rd phase of clinical trial for fracture prevention in Japan. It is expected that patients with a high fracture risk who could not take bisphosphonate orally receive the benefit of bisphosphonate through injection.